Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Study of 1592U89 in HIV-Infected Children Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on A Study of 1592U89 in HIV-Infected Children conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A Study of 1592U89 in HIV-Infected Children Clinical research trials and A Study of 1592U89 in HIV-Infected Children health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including A Study of 1592U89 in HIV-Infected Children. A Study of 1592U89 in HIV-Infected Children Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of 1592U89 in HIV-Infected Children clinical trial. Participants oftentimes recieve the most expert healthcare available for their A Study of 1592U89 in HIV-Infected Children condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A Study of 1592U89 in HIV-Infected Children

A Study of 1592U89 in HIV-Infected Children



A Study of 1592U89 in HIV-Infected Children

For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: The purpose of this study is to see if it is safe to give 1592U89 to children (aged 6 months until 14th birthday) with advanced HIV infection who have few treatment options available. The study also examines the effect 1592U89 has on the levels of HIV in the blood.
Details: This is an open-label, non-randomized study. All patients will be treated with 1592U89. Additionally, since optimal therapy usually includes the combined use of 2 or more antiretroviral agents in advanced patients, other novel antiretroviral therapies may be accessed through commercial means or via compassionate use programs. NOTE: 1592U89 should not be administered as a single new agent added to a failing treatment regimen.
Eligibility:
Study Type:  Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 6 Months/13 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Intravenous immunoglobulin G. - Erythropoietin, granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor, for the management of hematologic toxicity. Patients must have: - Documented HIV infection. - High risk for disease progression or mortality as defined by either of the following: - Viral load > 100,000 copies/ml and CD4 cells < 15% of total lymphocyte count despite at least 4 weeks of therapy with commercially available antiretrovirals or as a result of no therapy due to treatment-limiting toxicity of ZDV, 3TC, and ddI; or HIV-associated encephalopathy refractory to ZDV-containing regimen. - No access to any 1592U89 pediatric study where the patient could qualify for inclusion. - Parent or legal guardian with the ability to understand and provide written consent for the patient to participate in the trial. Study patients over 13 years should also give written informed consent whenever possible. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: - In the investigator's opinion, the patient is unlikely to comply with the requirements of the study. - Renal failure requiring dialysis. - Hepatic failure evident by Grade 3 or 4 hyperbilirubinemia and AST > 10 X upper limits of normal. - Life-threatening infection or other chronic disease that may interfere with taking 1592U89 or compromise the patient's safety. Patients with the following prior conditions are excluded: Documented hypersensitivity to 1592U89 or any other nucleoside analogue. See Inclusion - General Criteria.
Total Enrollment: 250

Location and Contact Information:

Glaxo Wellcome Inc
Research Triangle Park,  North Carolina,  277093398
United States
 


Additional Information:
Study ID Numbers:  238E;  CNAA3007
Study Start Date: 
Record last reviewed: December 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002197

Other Hiv Infections Studies:
1. Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

2. A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma

3. A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients

4. Antiviral Activity of and Resistance to Lamivudine in Combination with Zidovudine, Stavudine, or Didanosine

5. A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89

Related Studies:

Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials

A Study of 1592U89 in HIV-Infected Children
Modify your Search

  Other HIV Infections Clinical Trials
  Other North Carolina Clinical Trials
  Other Research Triangle Park Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103